Wendy Stevens to HIV-1
This is a "connection" page, showing publications Wendy Stevens has written about HIV-1.
Connection Strength
8,511
-
Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
Score: 0,386
-
Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clin Infect Dis. 2020 03 03; 70(6):1014-1020.
Score: 0,382
-
Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
Score: 0,305
-
Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015 May; 53(5):1616-21.
Score: 0,270
-
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
Score: 0,268
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
Score: 0,255
-
Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013 Dec; 194(1-2):300-7.
Score: 0,243
-
Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods. 2011 Mar; 172(1-2):78-80.
Score: 0,202
-
Should South Africa be performing nucleic acid testing on HIV enzyme-linked immunosorbent assay-negative samples? J Clin Microbiol. 2010 Sep; 48(9):3407-9.
Score: 0,195
-
Challenges in implementing HIV load testing in South Africa. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S78-84.
Score: 0,192
-
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
Score: 0,192
-
Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program. Pediatr Infect Dis J. 2009 Dec; 28(12):1123-5.
Score: 0,187
-
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010 Feb; 163(2):505-8.
Score: 0,187
-
Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme. BJOG. 2009 Dec; 116(13):1805-8.
Score: 0,185
-
Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods. 2009 Dec; 162(1-2):218-22.
Score: 0,184
-
Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol. 2009 Oct; 47(10):3400-2.
Score: 0,183
-
Ultra-high-throughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe Aptima HIV-1 screening assay. J Clin Microbiol. 2009 Aug; 47(8):2465-9.
Score: 0,181
-
Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009 Jul; 47(7):2209-17.
Score: 0,180
-
Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants. J Clin Microbiol. 2008 Dec; 46(12):3941-5.
Score: 0,173
-
Evaluation of the performance of the automated NucliSENS easyMAG and EasyQ systems versus the Roche AmpliPrep-AMPLICOR combination for high-throughput monitoring of human immunodeficiency virus load. J Clin Microbiol. 2007 Apr; 45(4):1244-9.
Score: 0,154
-
Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol Biotechnol. 2006 Feb; 32(2):101-10.
Score: 0,144
-
Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
Score: 0,136
-
Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005 Feb; 43(2):857-61.
Score: 0,134
-
Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods. 2005 Mar; 124(1-2):105-10.
Score: 0,133
-
Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J. 2004 Feb; 23(2):173-6.
Score: 0,125
-
The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis. PLoS Med. 2022 08; 19(8):e1004076.
Score: 0,113
-
Monitoring viral load for the last mile: what will it cost? J Int AIDS Soc. 2019 09; 22(9):e25337.
Score: 0,092
-
Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission. J Virol. 2019 07 01; 93(13).
Score: 0,091
-
Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay. PLoS One. 2016; 11(12):e0168244.
Score: 0,076
-
Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
Score: 0,076
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,075
-
Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 09 15; 214(6):873-83.
Score: 0,074
-
Improved Sensitivity of a Dual-Target HIV-1 Qualitative Test for Plasma and Dried Blood Spots. J Clin Microbiol. 2016 07; 54(7):1877-1882.
Score: 0,073
-
Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping. PLoS One. 2015; 10(7):e0131541.
Score: 0,069
-
CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. PLoS One. 2015; 10(3):e0115019.
Score: 0,068
-
Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis. 2014 Sep 01; 59(5):706-15.
Score: 0,064
-
Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014; 9(3):e86461.
Score: 0,063
-
Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):289-93.
Score: 0,062
-
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15; 207 Suppl 2:S70-7.
Score: 0,060
-
Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. J Clin Microbiol. 2013 Jun; 51(6):1899-905.
Score: 0,059
-
A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
Score: 0,059
-
The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301). PLoS One. 2012; 7(9):e42322.
Score: 0,057
-
Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
Score: 0,056
-
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 02; 367(5):399-410.
Score: 0,056
-
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
Score: 0,056
-
HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
Score: 0,055
-
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9.
Score: 0,055
-
Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
Score: 0,055
-
Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J Clin Virol. 2012 May; 54(1):21-5.
Score: 0,054
-
Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. BMC Pediatr. 2011 Nov 21; 11:104.
Score: 0,054
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
Score: 0,054
-
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr; 12(4):307-17.
Score: 0,053
-
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31.
Score: 0,053
-
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
Score: 0,053
-
Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):460-6.
Score: 0,052
-
Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient. Virus Genes. 2010 Dec; 41(3):358-60.
Score: 0,050
-
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):5-12.
Score: 0,050
-
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
Score: 0,050
-
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010 Sep 13; 5(9):e12598.
Score: 0,049
-
Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
Score: 0,049
-
HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):95-101.
Score: 0,049
-
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
Score: 0,049
-
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010 Jun 12; 375(9731):2092-8.
Score: 0,048
-
Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses. 2010 Apr; 26(4):489-93.
Score: 0,048
-
Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6. AIDS. 2010 Mar 13; 24(5):785-6.
Score: 0,048
-
Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS. 2009 Nov 27; 23(18):2459-66.
Score: 0,047
-
Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses. 2009 Nov; 25(11):1141-8.
Score: 0,047
-
Can oral fluid testing be used to replace blood-based HIV rapid testing to improve access to diagnosis in South Africa? J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5):646-8; author reply 648-9.
Score: 0,046
-
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009 Feb 20; 23(4):461-9.
Score: 0,044
-
Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009; 14(5):619-29.
Score: 0,044
-
Comparison of cervicovaginal lavage, cervicovaginal lavage enriched with cervical swab, and vaginal tampon for the detection of HIV-1 RNA and HSV-2 DNA in genital secretions. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):406-9.
Score: 0,044
-
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol. 2008 Sep; 46(9):2945-9.
Score: 0,043
-
Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses. 2008 May; 24(5):743-51.
Score: 0,042
-
Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS. 2008 Apr 23; 22(7):896-9.
Score: 0,042
-
The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625-39.
Score: 0,041
-
Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory. J Virol Methods. 2007 Dec; 146(1-2):397-400.
Score: 0,040
-
Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX primer for quantitation of human immunodeficiency virus type-1 (HIV-1). J Virol Methods. 2007 Dec; 146(1-2):14-21.
Score: 0,040
-
Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):322-30.
Score: 0,039
-
Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin Vaccine Immunol. 2007 Feb; 14(2):201-3.
Score: 0,038
-
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007 Mar 01; 25(11):2120-7.
Score: 0,038
-
HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006 Oct; 3(10):e417.
Score: 0,038
-
Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis. Clin Vaccine Immunol. 2006 Jan; 13(1):152-5.
Score: 0,036
-
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005 Dec; 43(12):5950-6.
Score: 0,036
-
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005 Aug 12; 19(12):1289-97.
Score: 0,035
-
Identifying acute HIV infection--a major new public health challenge. S Afr Med J. 2004 Jul; 94(7):531.
Score: 0,032
-
Diagnosis of human immunodeficiency virus infection in perinatally exposed orphaned infants in a resource-poor setting. Pediatr Infect Dis J. 2000 Oct; 19(10):1014-5.
Score: 0,025
-
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis. 2015 May 15; 60(10):1552-8.
Score: 0,017
-
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014; 9(2):e85869.
Score: 0,016
-
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
Score: 0,015
-
Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
Score: 0,013
-
Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sex Transm Infect. 2010 Feb; 86(1):46-50.
Score: 0,012